Natco Pharma updates on Risdiplam launch in India, Delhi High Court denies Roche's injunction plea, pricing set at ₹15,900.

The stock rose 2.95 per cent to hit a high of Rs 789. It was last seen trading 1.44 per cent up at Rs 777.45. At this price, it has crashed 44.42 per cent on a year-to-date (YTD) basis.

The Nifty Pharma index closed 0.41 per cent up at 21438.05. Benchmark NSE Nifty50 index ended up 41.71 points at 24167.25, ...

Natco Pharma, operating in the Pharmaceuticals sector and classified as a Smallcap on the BSE, currently has its share price at ₹826.85. The stock has experienced fluctuations today, with a low ...

Natco Pharma started in Hyderabad with an investment of ₹3.3 million in 1981 and 20 employees working at a single unit. Today ...

Format of Initial Disclosure to be made by an entity identified as a Large Corporate.<br/><br/> <table border=' ...

Natco Pharma has announced the supperannuation of Tummala Venkata Rao, Vice President - Production of the Company."With effect from the closure of business hours on 31st March, 2025, Mr.

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

Natco Pharma plans to launch generic Risdiplam pending Delhi High Court decision, offering discounts to patients.

The Company has received numerous enquiries from investors and patients about the launch, availability and pricing of generic version of Risdiplam in the Indian market. The Company wishes to clarify ...

Natco Pharma Limited is a vertically integrated and R&D focused pharmaceutical company that specialises in development, manufacturing and marketing of Finished Dosage Formulations (FDF ...

Nifty Pharma has fallen by 12.8 per cent so far this year, with Natco Pharma and Granules India leading the plunge ...